• Chemomab Therapeutics posted a Q1 net loss of $1.8 million, narrowing from a $3.3 million loss a year earlier.
• R&D expense fell to $0.9 million from $2.5 million, due to continued winding down of activities related to the Phase 2 SPRING trial; G&A expense edged down to $0.9 million from $1.0 million.
• Cash, cash equivalents and short-term bank deposits declined to $8.0 million as of March 31, 2026, from $10.4 million at end-2025, with runway expected to fund operations through end of Q1 2027.
• Company highlighted new SPRING Phase 2 analyses showing nebokitug drove dose-dependent reductions in PSC-related fibrotic and immune signatures, with additional proteomic signals suggesting potential benefit in PSC patients with co-existing ulcerative colitis or Crohn's disease.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chemomab Therapeutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178913-26-002672), on May 14, 2026, and is solely responsible for the information contained therein.